Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy

Published:2021-02-04 Issue:4 Volume:106 Page:574-583
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur. J. Haematol.

Author:

Abdayem Pamela¹²^ORCID,Ibrahim Nathalie¹,El Dakdouki Yolla¹,Willekens Christophe¹,Ghez David¹,A. Rouche Julia³,Dartigues Peggy⁴,Desmaris Romain⁵,Danu Alina¹,Rossignol Julien¹,Lazarovici Julien¹,Fermé Christophe¹,Ribrag Vincent¹⁶,Michot Jean M.¹⁶^ORCID

Affiliation:

1. Department of Haematology Gustave Roussy Cancer Campus Villejuif France

2. Department of Cancer Medicine Gustave Roussy Cancer Campus Villejuif France

3. Department of Radiology Gustave Roussy Cancer Campus Villejuif France

4. Department of Pathology Gustave Roussy Cancer Campus Villejuif France

5. Department of Clinical Pharmacy Gustave Roussy Cancer Campus Villejuif France

6. Department of Early Drug Development (DITEP) Gustave Roussy Cancer Campus Villejuif France

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13589

Reference28 articles.

1. Impact of rituximab (rituxan) on the treatment of B‐cell non‐Hodgkin’s lymphoma;Dotan E;Pharm Ther,2010

2. Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma

3. Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

4. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

5. Treatment of Non-Hodgkin's Lymphoma

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytarabine;Reactions Weekly;2021-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3